SV2006002212A - Produccion de a-betaq ref.2004658-0076 - Google Patents
Produccion de a-betaq ref.2004658-0076Info
- Publication number
- SV2006002212A SV2006002212A SV2005002212A SV2005002212A SV2006002212A SV 2006002212 A SV2006002212 A SV 2006002212A SV 2005002212 A SV2005002212 A SV 2005002212A SV 2005002212 A SV2005002212 A SV 2005002212A SV 2006002212 A SV2006002212 A SV 2006002212A
- Authority
- SV
- El Salvador
- Prior art keywords
- cumulative
- culture
- accumulative
- glutamine
- amino acid
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 230000001186 cumulative effect Effects 0.000 abstract 6
- 235000001014 amino acid Nutrition 0.000 abstract 3
- 229940024606 amino acid Drugs 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 2
- 229960001230 asparagine Drugs 0.000 abstract 2
- 235000009582 asparagine Nutrition 0.000 abstract 2
- 238000009825 accumulation Methods 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 238000012136 culture method Methods 0.000 abstract 1
- 229910001410 inorganic ion Inorganic materials 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/04—Plant cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
UN SISTEMA MEJORADO PARA LA PRODUCCIÓN A GRAN ESCALA DE PROTEÍNAS Y/O A-BETA EN CULTIVO CELULAR, PARTICULARMENTE EN MEDIOS CARACTERIZADOS POR UNO O MÁS DE : I) UNA CONCENTRACIÓN ACUMULATIVA DE AMINOÁCIDO MAYOR DE UNOS 70 MM; II) UNA GLUTAMINA MOLAR ACUMULATIVA A UNA PROPORCIÓN DE ASPARAGINA ACUMULATIVA MENOR DE UNOS 2; III) UNA GLUTAMINA MOLARA ACUMULATIVA A PROPORCIÓN TOTAL ACUMULATIVA DEL AMINOÁCIDO MENOR DE UNOS 0.2; IV) UN ION INORGÁNICO MOLAR ACUMULATIVO A LA PROPRCIÓN TOTAL ACUMULATIVA DE AMINOÁCIDO ENTRE UNOS 0.4 A 1; Ó SE PROPORICONA V) UNA CONCENTRACIÓN COMBINADA CUMULATIVA DE GLUTAMINA Y ACUMULATIVA DE ASPARAGINA ENTRE UNOS 16 Y36 MM. EL USO DE DICHO SISTEMA PERMITE LOS ALTOS NIVELES DE LA PRODUCCIÓN DE A-BETA Y AMINORA LA ACUMULACIÓN DE CIERTOS FACTORES INDESEABLES COMO AMONIO Y/O LACTATO. ADICIONALMENTE, SE PROPORCIONAN LOS MÉTODOS DE CULTIVO QUE INCLUYEN UN CAMBIO DE TEMPERATURA, TÍPICAMENTE INCLUYENDO UNA DISMINUCIÓN EN LA TEMPERATURA CUANDO EL CULTIVO HAYA ALCANZADO UN 20-80% DE SU MÁXIMA DENSIDAD CELULAR. ALTERNATIVA O ADICIONALMENTE, ESTE INVENTO BRINDA LOS MÉTODOS DE MOSO QUE, DESPUÉS DE ALCANZAR UN MÁXIMO, LOS NIVELES DE LACTATO Y/O AMONIO EN EL CULTIVO DISMINUYAN EN TIEMPO EXTRA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60493604P | 2004-08-27 | 2004-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2006002212A true SV2006002212A (es) | 2006-06-26 |
Family
ID=35500647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2005002212A SV2006002212A (es) | 2004-08-27 | 2005-08-26 | Produccion de a-betaq ref.2004658-0076 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7335491B2 (es) |
| EP (2) | EP1781803B1 (es) |
| JP (3) | JP2008511328A (es) |
| KR (1) | KR100998857B1 (es) |
| CN (1) | CN101048512B (es) |
| AR (1) | AR050471A1 (es) |
| AU (1) | AU2005280090A1 (es) |
| BR (1) | BRPI0514680A (es) |
| CA (1) | CA2578137C (es) |
| CR (1) | CR8996A (es) |
| EC (1) | ECSP077351A (es) |
| EG (1) | EG25848A (es) |
| ES (1) | ES2599103T3 (es) |
| HN (1) | HN2005000486A (es) |
| IL (1) | IL181587A (es) |
| MX (1) | MX2007002382A (es) |
| MY (1) | MY146097A (es) |
| NO (1) | NO20071571L (es) |
| NZ (1) | NZ591233A (es) |
| PE (2) | PE20100147A1 (es) |
| RU (1) | RU2418858C2 (es) |
| SG (1) | SG155250A1 (es) |
| SV (1) | SV2006002212A (es) |
| TW (1) | TWI374935B (es) |
| UA (1) | UA89644C2 (es) |
| WO (1) | WO2006026408A2 (es) |
| ZA (1) | ZA200702487B (es) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| PE20070796A1 (es) * | 2005-10-24 | 2007-08-15 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| US20070231895A1 (en) * | 2005-11-02 | 2007-10-04 | Lee Gene W | Methods for adapting mammalian cells |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| EP2808032B1 (en) * | 2005-12-12 | 2018-08-01 | AC Immune S.A. | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| KR101495549B1 (ko) * | 2006-07-13 | 2015-02-25 | 와이어쓰 엘엘씨 | 당단백질의 생산 |
| CL2007002070A1 (es) | 2006-07-14 | 2008-02-08 | Ac Immune S A Genentech Inc | Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade |
| WO2008055260A2 (en) * | 2006-11-03 | 2008-05-08 | Wyeth | Glycolysis-inhibiting substances in cell culture |
| JP5564259B2 (ja) | 2006-11-08 | 2014-07-30 | ワイス・エルエルシー | 細胞培養のための合理的に設計された培地 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) * | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
| KR20090127326A (ko) * | 2007-03-02 | 2009-12-10 | 와이어쓰 | 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도 |
| EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| WO2008136398A1 (ja) | 2007-04-26 | 2008-11-13 | Chugai Seiyaku Kabushiki Kaisha | 高濃度アミノ酸含有培地を用いた細胞の培養方法 |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| BRPI0812478A2 (pt) * | 2007-06-12 | 2017-05-16 | Ac Immune Sa | anticorpo quimérico ou um fragmento do mesmo, ou anticorpo humanizado ou um fragmento do mesmo, molécula de ácido nucleico, vetor de expressão, célula, composição, métodos de prevenir, tratar ou aliviar os efeitos d euma ou mais doenças, de diagnosticar uma doença ou condição associada com amilóide em um indivíduo, de determinar a extensão de carga de placa amiloidogênica em um tecido e/ou fluidos corporais de um indivíduo, de desagregar fibras beta-amilóides pré-formadas e de prevenir degradação de neurônios induzidas por abeta, kit de teste, região variável de cadeia, e, linhagem de célula |
| AU2008311367B2 (en) * | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| CA2720980C (en) * | 2008-04-17 | 2014-02-25 | Wyeth Llc | Methods for enhanced production of bone morphogenetic proteins |
| KR20150126739A (ko) | 2008-09-15 | 2015-11-12 | 제넨테크, 인크. | 세포 오스몰농도를 조절하기 위한 조성물 및 방법 |
| KR101822205B1 (ko) | 2009-08-11 | 2018-01-25 | 제넨테크, 인크. | 글루타민-비함유 세포 배양 배지에서의 단백질의 생성 |
| EP2475428B1 (en) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| US8470552B2 (en) * | 2009-10-12 | 2013-06-25 | Keck Graduate Institute | Strategy to reduce lactic acid production and control PH in animal cell culture |
| US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| PT3330370T (pt) | 2010-04-26 | 2021-05-11 | Novartis Ag | Processo para cultivo de células cho |
| DK2563904T3 (en) | 2010-04-26 | 2015-04-07 | Novartis Ag | Improved cell culture medium |
| MX2012012525A (es) * | 2010-04-26 | 2012-11-23 | Novartis Ag | Medio de cultivo mejorado. |
| WO2012016173A2 (en) | 2010-07-30 | 2012-02-02 | Ac Immune S.A. | Safe and functional humanized antibodies |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| WO2012023085A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
| DK2686313T3 (en) | 2011-03-16 | 2016-05-02 | Probiodrug Ag | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| LT2726600T (lt) * | 2011-07-01 | 2017-05-25 | Amgen Inc. | Žinduolių ląstelių kultūra |
| FI20115704L (fi) | 2011-07-01 | 2013-01-02 | Teknologian Tutkimuskeskus Vtt Oy | Vierasproteiinien tuoton parantaminen |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US11390663B2 (en) | 2013-10-11 | 2022-07-19 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
| MX2016004564A (es) | 2013-10-11 | 2016-07-12 | Regeneron Pharma | Cultivo celular metabolicamente optimizado. |
| DE102017203908B3 (de) * | 2017-03-09 | 2018-05-30 | Evonik Technochemie Gmbh | Kulturmedium, umfassend Oligopeptide |
| EP3638772A1 (en) * | 2017-06-16 | 2020-04-22 | Katholieke Universiteit Leuven | Cell culture media for differentiation of stem cells into hepatocytes |
| DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
| EP3818078B1 (en) * | 2018-07-03 | 2024-02-28 | Bristol-Myers Squibb Company | Methods of producing recombinant proteins |
| MY190626A (en) | 2019-12-06 | 2022-04-27 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
| US20230106023A1 (en) | 2020-02-18 | 2023-04-06 | Boehringer Ingelheim International Gmbh | Mammalian cell culture processes |
| CN116348487A (zh) | 2020-07-23 | 2023-06-27 | 欧萨尔普罗席纳有限公司 | 抗淀粉样β抗体 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5672502A (en) * | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU632065B2 (en) * | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| US6291159B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| ATE168416T1 (de) | 1989-10-05 | 1998-08-15 | Optein Inc | Zellfreie synthese und isolierung von genen und polypeptiden |
| US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5538983A (en) * | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
| US5156964A (en) * | 1990-08-16 | 1992-10-20 | Cetus Corporation | Methods for adapting cells for increased product production through exposure to ammonia |
| US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| GB2251249B (en) | 1990-12-28 | 1995-06-21 | Mogam Biotech Res Inst | High-density medium for animal cell culture |
| JPH059735A (ja) * | 1991-07-09 | 1993-01-19 | Kobe Steel Ltd | ダイヤモンドの気相合成方法 |
| GB9118664D0 (en) | 1991-08-30 | 1991-10-16 | Celltech Ltd | Cell culture |
| US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| JP3504963B2 (ja) | 1993-10-22 | 2004-03-08 | 智靖 羅 | 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片 |
| US6310185B1 (en) * | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
| US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| US5721121A (en) * | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| JP4306813B2 (ja) * | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
| KR20000010825A (ko) * | 1996-05-08 | 2000-02-25 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 종양괴사인자 수용체-면역 글로불린 융합 단백질을 사용한 천식의 치료방법 |
| US6156570A (en) * | 1997-03-20 | 2000-12-05 | Regents Of The University Of Minnesota | Process for the continuous culture of cells |
| US20020012991A1 (en) * | 1997-04-07 | 2002-01-31 | Florence Chua Nee Ho Kit Fong | Cell culture media for enhanced protein production |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| EP1150688A4 (en) | 1998-10-19 | 2004-06-16 | Yeda Res & Dev | TREATING SYSTEMIC LUPUS ERYTHEMATODES BY REGULATING THE AUTOIMMUNE RESPONSE TO AUTOANTIGENS |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| WO2002088307A2 (en) | 2001-04-30 | 2002-11-07 | Eli Lilly And Company | Humanized antibodies |
| DE60230736D1 (de) | 2001-04-30 | 2009-02-26 | Lilly Co Eli | HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9; |
| AU2002316230A1 (en) | 2001-06-13 | 2002-12-23 | Genentech, Inc. | Methods of culturing animal cells and polypeptide production in animal cells |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| BR0307871A (pt) | 2002-02-21 | 2005-04-12 | Wyeth Corp | Proteìnas contendo domìnio de folistatina |
| PL375045A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Gasp1: a follistatin domain containing protein |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| BR122019027974B1 (pt) | 2002-05-02 | 2022-06-14 | Wyeth Holdings Corporation | Composição compreendendo conjugado monomérico de derivado de caliqueamicina/anticorpo anti-cd22 e seu uso |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
-
2005
- 2005-08-25 TW TW094129074A patent/TWI374935B/zh not_active IP Right Cessation
- 2005-08-25 US US11/213,317 patent/US7335491B2/en not_active Expired - Fee Related
- 2005-08-26 MX MX2007002382A patent/MX2007002382A/es active IP Right Grant
- 2005-08-26 MY MYPI20054022A patent/MY146097A/en unknown
- 2005-08-26 BR BRPI0514680-1A patent/BRPI0514680A/pt not_active Application Discontinuation
- 2005-08-26 NZ NZ591233A patent/NZ591233A/xx not_active IP Right Cessation
- 2005-08-26 JP JP2007530148A patent/JP2008511328A/ja active Pending
- 2005-08-26 SG SG200905720-9A patent/SG155250A1/en unknown
- 2005-08-26 EP EP05791655.3A patent/EP1781803B1/en active Active
- 2005-08-26 RU RU2007108718/10A patent/RU2418858C2/ru not_active IP Right Cessation
- 2005-08-26 UA UAA200703284A patent/UA89644C2/ru unknown
- 2005-08-26 PE PE2009001268A patent/PE20100147A1/es not_active Application Discontinuation
- 2005-08-26 PE PE2005000986A patent/PE20060715A1/es not_active Application Discontinuation
- 2005-08-26 KR KR1020077004809A patent/KR100998857B1/ko not_active IP Right Cessation
- 2005-08-26 SV SV2005002212A patent/SV2006002212A/es unknown
- 2005-08-26 CA CA2578137A patent/CA2578137C/en not_active Expired - Fee Related
- 2005-08-26 HN HN2005000486A patent/HN2005000486A/es unknown
- 2005-08-26 CN CN2005800368972A patent/CN101048512B/zh not_active Expired - Fee Related
- 2005-08-26 EP EP10184494A patent/EP2348126A3/en not_active Withdrawn
- 2005-08-26 ES ES05791655.3T patent/ES2599103T3/es active Active
- 2005-08-26 AR ARP050103595A patent/AR050471A1/es not_active Application Discontinuation
- 2005-08-26 WO PCT/US2005/030364 patent/WO2006026408A2/en active Application Filing
- 2005-08-26 AU AU2005280090A patent/AU2005280090A1/en not_active Abandoned
-
2007
- 2007-02-27 EG EGNA2007000224 patent/EG25848A/xx active
- 2007-02-27 IL IL181587A patent/IL181587A/en not_active IP Right Cessation
- 2007-03-16 CR CR8996A patent/CR8996A/es unknown
- 2007-03-26 ZA ZA2007/02487A patent/ZA200702487B/en unknown
- 2007-03-26 NO NO20071571A patent/NO20071571L/no not_active Application Discontinuation
- 2007-03-27 EC EC2007007351A patent/ECSP077351A/es unknown
-
2012
- 2012-02-17 JP JP2012033105A patent/JP2012095671A/ja active Pending
-
2015
- 2015-04-01 JP JP2015075425A patent/JP2015133980A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2006002212A (es) | Produccion de a-betaq ref.2004658-0076 | |
| SV2006002211A (es) | Produccion de tnfr-ig ref.2004658-0091 | |
| AR051017A1 (es) | Produccion de polipeptidos | |
| TR201806812T4 (tr) | Rna-yönlendirmeli hedef dna modifikasyonu için ve rna-yönlendirmeli transkripsiyon modifikasyonu için yöntemler ve bileşimler. | |
| EA201992795A1 (ru) | Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе | |
| GT200600112A (es) | Composiciiones de tigeciclina y metodos de preparacion | |
| CL2007001335A1 (es) | Anticuerpo anti cd40; acido nucleico que lo codifica; celula; cultivo celular; metodo de produccion; composicion farmaceutica; metodo para seleccionar un anticuerpo anti cd40; y su uso para tratar sintomas de un trastorno autoinmune y/o un trastorno inflamatorio y/o para reducir el rechazo al injerto y/o para el tratamiento de cancer positivos a cd40. | |
| IN2012DN02452A (es) | ||
| BRPI0516572A (pt) | métodos e composições para melhorar a produção de proteìnas recombinantes | |
| EA201291024A1 (ru) | Композиции эндорибонуклеаз и способы их использования | |
| DK1846974T3 (da) | Membran-elektrode samlinger til brændstofceller, deres fremstilling og anvendelse og brændstofceller indeholdende disse | |
| CY1112394T1 (el) | Παραγωγη fgf18 σε προκαρυωτικους ξενιστες | |
| WO2010056831A3 (en) | Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator | |
| EA202090067A2 (ru) | Способ получения рекомбинантного adamts13 в культуре клеток | |
| BRPI0612424A2 (pt) | composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas | |
| WO2007130664A3 (en) | Derivation of embryonic stem cells and embryo-derived cells | |
| BR112014016049A8 (pt) | métodos de isolamento de (4-cloro-2-fluor-3- substituído-fenil)boronatos e métodos de uso dos mesmos | |
| AR057553A1 (es) | Composicion portadora para el suministro de un acido nucleico | |
| BR112018007138A8 (pt) | célula eletroquímica de óxido sólido tubular, suportada por eletrodo | |
| BR112021019657A2 (pt) | Método para produzir célula knock-in | |
| DE502006007928D1 (de) | Feste salzzubereitung, deren herstellung und verwendung | |
| DE602006006206D1 (de) | Schnelle reduktion von iodspezies zu iodid | |
| UY37208A (es) | Tolerancia a herbicidas mediada por efectores de tipo activ ador 25 de transcripción (tal) | |
| Vafaei-Najafabadi et al. | Numerical study of long CO2 laser pulse interactions with hydrogen plasma at ATF | |
| CO2022008795A2 (es) | Método de marcaje de un hidrocarburo de petróleo |